Table 3. Prevalence of clinically active trachoma at baseline, 12 months and 24 months in children aged 0–9 years by treatment arm and subkebele.
| Prevalence of clinically active trachoma (trachomatous inflammation follicular and/or trachomatous inflammation intense) in children aged 0–9 years | |||||||
|---|---|---|---|---|---|---|---|
| Arma | Subkebele | Baseline | 12 Months | 24 Months | |||
| % | n/N | % | n/N | % | n/N | ||
| Single treatment only | 1 | 95.8 | (46/48) | 64.0 | (32/50) | 83.7 | (41/49) |
| 2 | 78.2 | (43/55) | 62.3 | (33/53) | 68.0 | (34/50) | |
| 3 | 83.7 | (41/49) | 73.7 | (28/38) | 50.0 | (25/50) | |
| 4 | 85.1 | (40/47) | 60.0 | (30/50) | 54.7 | (29/53) | |
| 5 | 41.5 | (22/53) | 40.0 | (20/50) | 5.8 | (3/52) | |
| 6 | 80.4 | (45/56) | 46.2 | (24/52) | 22.0 | (11/50) | |
| 7 | 76.0 | (38/50) | 46.0 | (23/50) | 37.5 | (18/48) | |
| 8 | 26.5 | (13/49) | 64.0 | (32/50) | 40.0 | (20/50) | |
| 9 | 46.2 | (24/52) | 64.0 | (32/50) | 30.0 | (15/50) | |
| 10 | 76.0 | (38/50) | 58.8 | (30/51) | 61.2 | (30/49) | |
| 11 | 24.5 | (12/49) | 54.9 | (28/51) | 76.5 | (39/51) | |
| 12 | 21.3 | (10/47) | 47.1 | (24/51) | 52.1 | (25/48) | |
| Average (95% CI) | 61.3 | (44.0–78.5) | 56.8 | (50.4–63.1) | 48.5 | (34.0–62.9) | |
| Single treatment plus intensive latrine promotion | 13 | 83.3 | (40/48) | 59.6 | (31/52) | 64.0 | (32/50) |
| 14 | 70.6 | (36/51) | 66.7 | (34/51) | 30.0 | (15/50) | |
| 15 | 89.8 | (44/49) | 38.5 | (20/52) | 36.8 | (21/57) | |
| 16 | 91.8 | (45/49) | 40.0 | (20/50) | 42.0 | (21/50) | |
| 17 | 22.0 | (11/50) | 38.0 | (19/50) | 41.2 | (21/51) | |
| 18 | 88.7 | (47/53) | 59.6 | (31/52) | 32.0 | (16/50) | |
| 19 | ND | 53.4 | (31/58) | 54.0 | (27/50) | ||
| 20 | 53.1 | (26/49) | 90.2 | (46/51) | 68.0 | (34/50) | |
| 21 | 78.0 | (39/50) | 31.9 | (15/47) | 26.0 | (13/50) | |
| 22 | 73.6 | (39/53) | 61.1 | (33/54) | 72.0 | (36/50) | |
| 23 | 68.5 | (37/54) | 52.9 | (27/51) | 45.8 | (22/48) | |
| 24 | 72.3 | (34/47) | 50.0 | (25/50) | 37.3 | (19/51) | |
| Average (95% CI) | 72.0 | (58.2–85.5) | 53.5 | (43.4–63.6) | 45.8 | (36.0–55.6) | |
a
All subkebeles in both treatment arms were treated with a single mass azithromycin distribution at baseline.
ND: No data: examination team conducted clinical exam and swabbed the wrong subkebele.